CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

1 year ago

Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel GoldlustAccess the segment…

AI/ML Innovations Inc. Announces Impairment of Investment

1 year ago

VICTORIA, BC / ACCESSWIRE / October 10, 2024 / AI/ML Innovations Inc. ("AI/ML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) announces that, as…

International Myeloma Foundation Launches Clinical Trial Matching Engine in Partnership with SparkCures

1 year ago

SparkCures’ best-in-class clinical trial matching and navigation service is now accessible via myeloma.org.STUDIO CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE)…

Alpha Tau Treats First Patient with Recurrent Lung Cancer

1 year ago

JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the…

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

1 year ago

DOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company…

Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program

1 year ago

Company’s VP of Education and Global Training Named Chairman of ASRM Corporate Member CouncilATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) --…

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

1 year ago

– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical…

SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation

1 year ago

SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated…

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site

1 year ago

FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) --…

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

1 year ago

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing…